These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33454385)

  • 41. Multifunctional Peptide-Amphiphile End-Capped Mesoporous Silica Nanoparticles for Tumor Targeting Drug Delivery.
    Cheng YJ; Zhang AQ; Hu JJ; He F; Zeng X; Zhang XZ
    ACS Appl Mater Interfaces; 2017 Jan; 9(3):2093-2103. PubMed ID: 28032742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles.
    Tsai CH; Vivero-Escoto JL; Slowing II; Fang IJ; Trewyn BG; Lin VS
    Biomaterials; 2011 Sep; 32(26):6234-44. PubMed ID: 21684000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mesoporous silica nanoparticles in nanomedicine applications.
    Manzano M; Vallet-Regí M
    J Mater Sci Mater Med; 2018 May; 29(5):65. PubMed ID: 29737405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances in mesoporous silica nanoparticle-based targeted drug-delivery systems for cancer therapy.
    Li Y; Deng G; Hu X; Li C; Wang X; Zhu Q; Zheng K; Xiong W; Wu H
    Nanomedicine (Lond); 2022 Aug; 17(18):1253-1279. PubMed ID: 36250937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controllable synthesis of versatile mesoporous organosilica nanoparticles as precision cancer theranostics.
    Cheng Y; Jiao X; Fan W; Yang Z; Wen Y; Chen X
    Biomaterials; 2020 Oct; 256():120191. PubMed ID: 32593907
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanoarchitectured Structure and Surface Biofunctionality of Mesoporous Silica Nanoparticles.
    Kankala RK; Han YH; Na J; Lee CH; Sun Z; Wang SB; Kimura T; Ok YS; Yamauchi Y; Chen AZ; Wu KC
    Adv Mater; 2020 Jun; 32(23):e1907035. PubMed ID: 32319133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tailoring Particle Size of Mesoporous Silica Nanosystem To Antagonize Glioblastoma and Overcome Blood-Brain Barrier.
    Mo J; He L; Ma B; Chen T
    ACS Appl Mater Interfaces; 2016 Mar; 8(11):6811-25. PubMed ID: 26911360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
    Zhang Q; Zhao H; Li D; Liu L; Du S
    Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery.
    Du X; Li X; Xiong L; Zhang X; Kleitz F; Qiao SZ
    Biomaterials; 2016 Jun; 91():90-127. PubMed ID: 27017579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery.
    Sábio RM; Meneguin AB; Ribeiro TC; Silva RR; Chorilli M
    Int J Pharm; 2019 Jun; 564():379-409. PubMed ID: 31028801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier.
    Baghirov H; Karaman D; Viitala T; Duchanoy A; Lou YR; Mamaeva V; Pryazhnikov E; Khiroug L; de Lange Davies C; Sahlgren C; Rosenholm JM
    PLoS One; 2016; 11(8):e0160705. PubMed ID: 27547955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biocompatibility of mesoporous silica nanoparticles.
    Asefa T; Tao Z
    Chem Res Toxicol; 2012 Nov; 25(11):2265-84. PubMed ID: 22823891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
    J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Silica nanoparticles: A review of their safety and current strategies to overcome biological barriers.
    Janjua TI; Cao Y; Kleitz F; Linden M; Yu C; Popat A
    Adv Drug Deliv Rev; 2023 Dec; 203():115115. PubMed ID: 37844843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers.
    Popat A; Hartono SB; Stahr F; Liu J; Qiao SZ; Qing Max Lu G
    Nanoscale; 2011 Jul; 3(7):2801-18. PubMed ID: 21547299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Facile pathway to construct mesoporous silica nanoparticles loaded with pyraclostrobin: Physicochemical properties, antifungal activity, and biosafety.
    Feng J; Chen Z; Chen W; Sun L; Yang J; He K; Dong S; Yuan S
    Pest Manag Sci; 2022 Jun; 78(6):2332-2341. PubMed ID: 35246931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers.
    Gao Y; He Y; Zhang H; Zhang Y; Gao T; Wang JH; Wang S
    J Colloid Interface Sci; 2021 Jan; 582(Pt A):364-375. PubMed ID: 32861041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
    Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
    Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications.
    Živojević K; Mladenović M; Djisalov M; Mundzic M; Ruiz-Hernandez E; Gadjanski I; Knežević NŽ
    J Control Release; 2021 Sep; 337():193-211. PubMed ID: 34293320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
    Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
    Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.